Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
HLA ; 102(4): 552-553, 2023 10.
Artigo em Inglês | MEDLINE | ID: mdl-37334898

RESUMO

The novel HLA class II allele HLA-DPB1*1485:01 is described.


Assuntos
Medula Óssea , Doadores de Tecidos , Humanos , Alelos , Cadeias beta de HLA-DP/genética
2.
3.
Oncol Lett ; 15(6): 9174-9182, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29805648

RESUMO

Anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC) are very aggressive cancers whose histological diagnosis is not always straightforward. Clinical, pathological and genetic features may be useful to improve the identification of these rare histotypes. In the present study the clinical, pathological and genetic features of two groups of ATC (n=21) and PDTC (n=21) patients were analyzed. Clinical data were retrieved from a computerized database. The oncogenic profiles were studied using the Sanger sequencing method of a selected series of oncogenes and/or tumor suppressor genes known to be altered in these tumors. The presence of macrophages in both series of tissues was evaluated by immunohistochemistry. Patients with ATC were older and affected by a more advanced disease at diagnosis than those with PDTC. The median survival was significantly shorter in ATC compared with PDTC patients (P=0.0014). ATC showed a higher prevalence of TP53 and TERT mutations (10/21, 47.6% and 9/21, 42.8%, respectively) while TERT and BRAF mutations were the most prevalent in the PDTC group (7/21, 33.3% and 4/23, 19% respectively). Genetic heterogeneity (i.e., >2 mutations) was more frequent in ATC (10/21, 28.6%) compared with in PDTC (3/21, 4.7%) (P=0.03). Macrophages were more frequently present in ATC, particularly in those cases with TP53 mutations. In conclusion, these data indicate that ATC and PDTC may be characterized by different clinical, pathological and genetic profiles. In particular ATC, but not PDTC, were positive for TP53 and PTEN alterations. Complex mutations were also found in ATC but not in PDTC. Moreover, genetic heterogeneity was more frequent in ATC than PDTC. Finally, TP53 mutation and the accumulation of several mutations correlated with a shorter survival time.

4.
Cytotherapy ; 18(2): 205-18, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26794713

RESUMO

BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) modulate the immune response and represent a potential treatment for inflammatory and autoimmune diseases. We hypothesized that this feature could be potentiated by co-administering anti-inflammatory cytokines. In this article, we asked whether engineering of Wharton Jelly-derived human MSCs (WJ-hMSCs) to express an anti-inflammatory cytokine increases cell immunomodulatory properties without altering their native features. METHODS: We used Epstein-Barr virus-derived interleukin-10 (vIL-10), which shares some immunosuppressive properties with human IL-10 but lacks immunostimulatory activity. Engineering was accomplished by transducing WJ-hMSCs with a self-inactivating feline immunodeficiency virus-derived vector co-expressing vIL-10 and herpes simplex virus type-1 thymidine kinase (TK). TK was added to allow future tracking of WJ-hMSC in vivo by positron electron tomography (PET). RESULTS: The results show that (i) expression of TK and/or vIL-10 does not change WJ-hMSC phenotypic and functional properties; (ii) vIL-10 is secreted, biologically active and enhances the immunosuppressing functions of WJ-hMSCs; (iii) v-IL10 and TK can be produced simultaneously by the same cells and do not interfere with each other. DISCUSSION: WJ-hMSCs engineered to secrete vIL-10 could be a powerful tool for adoptive cell therapy of immune-mediated diseases, and therefore, additional studies are warranted to confirm their efficacy in suitable animal disease models.


Assuntos
Interleucina-10/metabolismo , Timidina Quinase/metabolismo , Geleia de Wharton/citologia , Animais , Linhagem Celular , Células HEK293 , Herpesvirus Humano 4/genética , Humanos , Vírus da Imunodeficiência Felina/genética , Terapia de Imunossupressão , Imunossupressores , Imunoterapia Adotiva/métodos , Interleucina-10/genética , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/imunologia , Timidina Quinase/genética , Geleia de Wharton/metabolismo
5.
Biochim Biophys Acta ; 1832(1): 263-74, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23069389

RESUMO

Overactivation of glutamate receptors contributes to neuronal damage (excitotoxicity) in ischemic stroke but the detailed mechanisms are not fully elucidated. Brain ischemia is also characterized by an impairment of the activity of the proteasome, one of the major proteolytic systems in neurons. We found that excitotoxic stimulation with glutamate rapidly decreases ATP levels and the proteasome activity, and induces the disassembly of the 26S proteasome in cultured rat hippocampal neurons. Downregulation of the proteasome activity, leading to an accumulation of ubiquitinated proteins, was mediated by calcium entry through NMDA receptors and was only observed in the nuclear fraction. Furthermore, excitotoxicity-induced proteasome inhibition was partially sensitive to cathepsin-L inhibition and was specifically induced by activation of extrasynaptic NMDA receptors. Oxygen and glucose deprivation induced neuronal death and downregulated the activity of the proteasome by a mechanism dependent on the activation of NMDA receptors. Since deubiquitinating enzymes may regulate proteins half-life by counteracting ubiquitination, we also analyzed how their activity is regulated under excitotoxic conditions. Glutamate stimulation decreased the total deubiquitinase activity in hippocampal neurons, but was without effect on the activity of Uch-L1, showing that not all deubiquitinases are affected. These results indicate that excitotoxic stimulation with glutamate has multiple effects on the ubiquitin-proteasome system which may contribute to the demise process in brain ischemia and in other neurological disorders.


Assuntos
Regulação para Baixo , Ácido Glutâmico/metabolismo , Hipocampo/metabolismo , Neurônios/metabolismo , Complexo de Endopeptidases do Proteassoma/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Ubiquitina/metabolismo , Trifosfato de Adenosina/metabolismo , Animais , Isquemia Encefálica/enzimologia , Isquemia Encefálica/genética , Isquemia Encefálica/metabolismo , Células Cultivadas , Feminino , Ácido Glutâmico/toxicidade , Hipocampo/citologia , Hipocampo/enzimologia , Humanos , Masculino , Neurônios/enzimologia , Complexo de Endopeptidases do Proteassoma/genética , Ratos , Ratos Wistar , Receptores de N-Metil-D-Aspartato/genética
6.
Growth Factors ; 30(4): 242-57, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22670840

RESUMO

The glial cell line-derived neurotrophic factor (GDNF) was first identified as a survival factor for midbrain dopaminergic neurons, but additional studies provided evidences for a role as a trophic factor for other neurons of the central and peripheral nervous systems. GDNF regulates cellular activity through interaction with glycosyl-phosphatidylinositol-anchored cell surface receptors, GDNF family receptor-α1, which might signal through the transmembrane Ret tyrosine receptors or the neural cell adhesion molecule, to promote cell survival, neurite outgrowth, and synaptogenesis. The neuroprotective effect of exogenous GDNF has been shown in different experimental models of focal and global brain ischemia, by local administration of the trophic factor, using viral vectors carrying the GDNF gene and by transplantation of GDNF-expressing cells. These different strategies and the mechanisms contributing to neuroprotection by GDNF are discussed in this review. Importantly, neuroprotection by GDNF was observed even when administered after the ischemic injury.


Assuntos
Isquemia Encefálica/patologia , Fator Neurotrófico Derivado de Linhagem de Célula Glial/metabolismo , Fármacos Neuroprotetores/farmacologia , Animais , Sobrevivência Celular , Regulação da Expressão Gênica , Glicosilfosfatidilinositóis/metabolismo , Humanos , Isquemia , Camundongos , Modelos Biológicos , Neuritos/metabolismo , Neurônios/metabolismo , Neurônios/patologia , Proteínas Proto-Oncogênicas c-ret/metabolismo , Transdução de Sinais , Sinapses/metabolismo
7.
Pharm Res ; 29(9): 2601-14, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22622510

RESUMO

PURPOSE: A polysaccharide-flavonoid conjugate was developend and proposed for the treatment of pancreatic ductal adenocarcinoma (PDAC). METHODS: The conjugate was synthesized by free radical grafting reaction between catechin and dextran. The chemical characterization of the conjugate was obtained by UV-Vis, 1H-NMR, FT-IR and GPC analyses, while the functionalization degree was determined by the Folin-Ciocalteu assay. The biological activity of the catechin-dextran conjugate was tested on two different cell lines derived from human pancreatic cancer (MIA PaCa-2 and PL45 cells), and the toxicity towards human pancreatic nestin-expressing cells evaluated. RESULTS: Both the cancer cell lines are killed when exposed to the conjugate, and undergo apoptosis after the incubation with catechin-dextran which resulted more effective in killing pancreatic tumor cells compared to the catechin alone. Moreover, our experimental data indicate that the conjugate was less cytotoxic to human pancreatic nestin-expressing cells which are considered a good model of non-neoplastic pancreatic cells. CONCLUSION: The suitability of newly synthesized Dextran-Catechin conjugate in the treatment of PDAC was proved confirming the high potential application of the proposed macromolecula system in the cancer therapy.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma Ductal Pancreático/tratamento farmacológico , Catequina/química , Dextranos/química , Neoplasias Pancreáticas/tratamento farmacológico , Antineoplásicos/química , Sequência de Bases , Linhagem Celular Tumoral , Cromatografia em Gel , Primers do DNA , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Espectroscopia de Ressonância Magnética , Reação em Cadeia da Polimerase em Tempo Real , Espectrofotometria Ultravioleta , Espectroscopia de Infravermelho com Transformada de Fourier
8.
Epigenetics ; 6(10): 1198-206, 2011 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-21931275

RESUMO

Leptin is a master regulator of energy homeostasis. Its expression, prevalently localized in adipocytes, is positively related to adipose mass. Epigenetics is emerging as an important contributor to the changes in gene expression undergone by adipose tissue during obesity. We herein investigated the involvement of methylation-dependent mechanisms in leptin regulation in humans. We studied the methylation profile of a 305 bp region in the leptin promoter and analyzed the correspondent leptin expression in visceral adipocyte fraction (AF) and stromal vascular fraction (SVF) of white adipose tissue (WAT) and liver. We found an inverse relationship between methylation and leptin expression with AF displaying a lower methylation density (8%) than SVF and liver (18%, 21%). We evidenced a hot spot region, which mostly differentiates AF versus liver. This includes C15 and 21, which are within the recognition sequences for the transcription factors Sp1 and C/EBP, and C22-23/24, flanking a TATA box. In vitro studies demonstrated that demethylation (by decitabine) increase or de novo activate leptin expression in primary fibroblasts and HeLa cells, respectively. A longitudinal study carried out in patients analyzed before and after bariatric surgery-induced weight loss indicated that in this case decrease in WAT leptin expression (about 50%) does not correspond to changes in promoter methylation density. In conclusion, methylation density in the leptin promoter constitutes one control level for cell type specific leptin expression, whereas weight-loss induced changes in leptin expression does not seem to be methylation-dependent.


Assuntos
Leptina/genética , Regiões Promotoras Genéticas , Adulto , Células Cultivadas , Metilação de DNA , Regulação da Expressão Gênica , Humanos , Gordura Intra-Abdominal/metabolismo , Leptina/metabolismo , Pessoa de Meia-Idade
9.
Hum Immunol ; 72(1): 1-4, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20951754

RESUMO

The axiom of human leukocyte incompatibility (HLA) incompatibility has always led scientists to consider cancer transmission between HLA-different individuals impossible. In fact, cancer transmission between individuals represents a frightening possibility in animal populations with limited HLA diversity or for rare cancers exploiting downregulation of HLA expression. We review here evidence from nonhuman models and settings for interhuman transmission.


Assuntos
Antígenos de Histocompatibilidade Classe I/imunologia , Imunocompetência/imunologia , Neoplasias/imunologia , Tumores Venéreos Veterinários/imunologia , Animais , Transfusão de Sangue , Humanos , Neoplasias/epidemiologia , Neoplasias/cirurgia , Transplante , Tumores Venéreos Veterinários/epidemiologia
10.
J Periodontol ; 82(7): 1018-24, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21189087

RESUMO

BACKGROUND: Periodontitis is a complex multifactorial disease and is typically polygenic in origin. Genes play a fundamental part in each biologic process forming complex networks of interactions. However, only some genes have a high number of interactions with other genes in the network and may, therefore, be considered to play an important role. In a preliminary bioinformatic analysis, five genes that showed a higher number of interactions were identified and termed leader genes. In the present study, we use real-time quantitative polymerase chain reaction (PCR) technology to evaluate the expression levels of leader genes in the leukocytes of 10 patients with refractory chronic periodontitis and compare the expression levels with those of the same genes in 24 healthy patients. METHODS: Blood was collected from 24 healthy human subjects and 10 patients with refractory chronic periodontitis and placed into heparinized blood collection tubes by personnel trained in phlebotomy using a sterile technique. Blood leukocyte cells were immediately lysed by using a kit for total RNA purification from human whole blood. Complementary DNA (cDNA) synthesis was obtained from total RNA and then real-time quantitative PCR was performed. PCR efficiencies were calculated with a relative standard curve derived from a five cDNA dilution series in triplicate that gave regression coefficients >0.98 and efficiencies >96%. The standard curves were obtained using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and growth factor receptor binding protein 2 (GRB2), casitas B-lineage lymphoma (CBL), nuclear factor-KB1 (NFKB1), and REL-A (gene for transcription factor p65) gene primers and amplified with 1.6, 8, 40, 200, and 1,000 ng/µL total cDNA. Curves obtained for each sample showed a linear relationship between RNA concentrations and the cycle threshold value of real-time quantitative PCR for all genes. Data were expressed as mean ± SE (SEM). The groups were compared to the analysis of variance. A probability value <0.01 was considered statistically significant. RESULTS: The present study agrees with the preliminary bioinformatics analysis. In our experiments, the association of pathology with the genes was statistically significant for GRB2 and CBL (P <0.01), and it was not statistically significant for REL-A and NFKB1. CONCLUSION: This article lends support to our preliminary hypothesis that assigned an important role in refractory aggressive periodontitis to leader genes.


Assuntos
Periodontite Agressiva/genética , Periodontite Crônica/genética , Reação em Cadeia da Polimerase/métodos , Adulto , Biologia Computacional , Progressão da Doença , Feminino , Proteína Adaptadora GRB2/genética , Regulação da Expressão Gênica/genética , Predisposição Genética para Doença/genética , Gliceraldeído-3-Fosfato Desidrogenases/genética , Humanos , Masculino , Pessoa de Meia-Idade , Subunidade p50 de NF-kappa B/genética , Proteína Oncogênica v-cbl/genética , Fator de Transcrição RelA/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA